AbbVie’s head of immunology clinical development, Kori Wallace, MD, PhD, discusses how combination therapies, translational science, and emerging immune-reset approaches could usher in a new era of treatment for inflammatory bowel disease and other autoimmune conditions.
Despite significant advances in treating inflammatory bowel disease (IBD) and other autoimmune conditions, many patients still fail to achieve lasting remission. In this video episode of the Applied Clinical Trials podcast, Kori Wallace, MD, PhD, vice president and global head of immunology clinical development at AbbVie, examines the biological complexity behind this persistent “efficacy ceiling” and the strategies being pursued to move beyond incremental gains.
Wallace explores the shift toward more stringent, tissue-based treatment targets; the potential of combining complementary mechanisms; and the ongoing search for biomarkers that can make precision medicine practical in immunology. She also dives into the promise of B-cell depletion and in vivo CAR-T approaches designed to reset the immune system, potentially opening a path toward deep, durable, drug-free remission.
Other conversation highlights include:
Click below to listen to the audio version and subscribe to the Applied Clinical Trials Podcast:
